Dong Chung Insider Sell
Natus Medical Inc Vice President Medical Affairs Dong Chung on the December 11, 2015 unloaded a total of 14,000 shares of the company valued by the market at roughly $682,920 USD. This is at average stock price per share of $48.8 USD. In the last month, he also unloaded shares with a market value $ USD. Dong Chung currently has ownership of 123,043 shares which are about 0.38% of the California-based company’s market capitalization. This unexpected sale occurred on 11/12/2015 and was filed with the Washington-based Security and Exchange Commission. The original filing is available for public review here.
The institutional sentiment increased to 0.98 in 2015 Q3. Its up 0.06, from 0.92 in 2015Q2. The ratio is positive, as 21 funds sold all Natus Medical Inc shares owned while 73 reduced positions. 20 funds bought stakes while 72 increased positions. They now own 27.30 million shares or 6.24% less from 29.12 million shares in 2015Q2.
Lyon Street Capital Llc holds 5.01% of its portfolio in Natus Medical Inc for 175,068 shares. Domini Social Investments Llc owns 7,331 shares or 4.72% of their US portfolio. Moreover, Beddow Capital Management Inc has 3.8% invested in the company for 229,995 shares. The Virginia-based Motley Fool Asset Management Llc has invested 3.47% in the stock. Rk Capital Management Llc, a Colorado-based fund reported 325,080 shares.
Since April 28, 2015, the stock had 0 insider purchases, and 6 selling transactions for $1.87 million net activity. Moore William M sold 9,994 shares worth $405,395. Traverso Kenneth M sold 18,541 shares worth $844,942. Gunst Robert A sold 4,000 shares worth $181,200. Hawkins James B sold 100,000 shares worth $4.21M. The insider Chung Dong Chune Christopher sold 26,000 shares worth $1.07 million.
The stock decreased 0.51% or $0.25 during the last trading session, hitting $48.8. About 381,702 shares traded hands or 44.00% up from the average. Natus Medical Inc (NASDAQ:BABY) has risen 30.90% since May 8, 2015 and is uptrending. It has outperformed by 33.92% the S&P500.
More notable recent Natus Medical Inc (NASDAQ:BABY) news were published by: Thestreet.com which released: “New Lifetime High For Natus Medical (BABY)” on December 02, 2015, also Fool.com with their article: “Adding Up Baby Steps at Natus Medical Inc.” published on April 22, 2015, Zacks.com published: “Natus Medical (BABY) Hits 52-Week High on Solid Q3 Results” on November 30, 2015. More interesting news about Natus Medical Inc (NASDAQ:BABY) were released by: Fool.com and their article: “Natus Medical Inc. Serves Up a New Business Model” published on January 28, 2015 as well as Fool.com‘s news article titled: “Natus Medical: This Baby Can Leverage” with publication date: October 21, 2015.
Natus Medical Incorporated is a well-known provider of newborn care and neurology healthcare services and products used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The company has a market cap of $1.62 billion.
According to Zacks Investment Research, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.” Get a free copy of the Zacks research report on Natus Medical Inc (BABY).
Natus Medical - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
